According to the Zhitong Financial App, Beckon Medical-B (02170) announced its interim results for the six months ended June 30, 2023. The group achieved revenue of RMB 85.546 million (same unit), an increase of 24.76% over the previous year; R&D expenses of RMB 63.724 million, an increase of 40% over the previous year; equity shareholders of the company should account for losses of 61.369 million yuan, with losses of 0.2 yuan per share.
During the reporting period, the company generated revenue from the sale of various test kits, testing and cryopreservation equipment and instruments, embryo culture equipment, embryo culture liquid and consumables, etc. The increase in revenue was mainly due to a steady increase in sales of PGT kits and an increase in sales of ultra-low temperature storage equipment.
With the company's accumulated innovative experience and channel advantages in the PGT field, the company has become a product supplier of full-scenario solutions in the field of assisted reproduction through independent R&D and industrial mergers and acquisitions. In addition to PGT test kits, the company has a variety of innovative equipment and instruments. Following successive pipeline and business breakthroughs in andrology laboratories, frozen storage laboratories, and software laboratories, the company also completed the Singapore BMX acquisition in June 2023, realized another key area - the layout of the embryo laboratory, filled the gap in the company's embryo culture products such as jet lag incubators and assisted reproduction solutions, marking that the most demanded products in the assisted reproduction industry have been incorporated into the company's product portfolio, bringing significant synergy to the company's business.
In the future, through the advantages established by the company in sales channels and customer accumulation, the company will combine various advantageous products to achieve sales, unleash the growth potential of the Chinese and international markets, and enable the company to quickly establish an advantageous position in market share.